Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 2, 2022
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
[ Wed, Mar 02nd 2022
] - WOPRAI
Tue, March 1, 2022
[ Tue, Mar 01st 2022
] - WOPRAI
[ Tue, Mar 01st 2022
] - WOPRAI
[ Tue, Mar 01st 2022
] - WOPRAI
Roanna Ruiz Maintained (AVIR) at Hold with Decreased Target to $9 on, Mar 1st, 2022
Roanna Ruiz of SVB Leerink, Maintained "Atea Pharmaceuticals, Inc." (AVIR) at Hold with Decreased Target from $10 to $9 on, Mar 1st, 2022.
Roanna has made no other calls on AVIR in the last 4 months.
There is 1 other peer that has a rating on AVIR. Out of the 1 peers that are also analyzing AVIR, 0 agree with Roanna's Rating of Hold.
This is the rating of the analyst that currently disagrees with Roanna
- Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Decreased Target to $7 on, Thursday, January 6th, 2022
